40 reports

Abstract: - Global Bipolar Disorder Therapeutics Market to Reach $5.4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Bipolar Disorder Therapeutics estimated at US$5 Billion in the year 2020, is projected to reach a revised size of US$5.4 Billion by 2027, growing at a CAGR of 1% over the analysis...

  • Bipolar Disorder
  • Antipsychotic
  • World
  • China
  • United States

Bipolar Disorder Market Report Overview Bipolar Disorder market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Bipolar Disorder market types and applications. It is a focused study on Bipolar Disorder market space including global and regional...

  • Bipolar Disorder
  • World
  • Health Provider Density

"Bipolar Disorder (Manic Depression) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Bipolar Disorder (Manic Depression). The marketed products information covers their product details, patents (US & EU), historical and forecasted sales...

  • Bipolar Disorder
  • World
  • United States
  • Health Expenditure

The ongoing clinical trial research report- “2019 Bipolar Disorder Ongoing Clinical Trials Study” analyzes the current scenario of all active Bipolar Disorder trials across the world. The report presents top level analysis of global Bipolar Disorder clinical trials across countries, companies and universities. It is designed to provide clear...

  • Bipolar Disorder
  • Clinical Trial
  • World
  • APAC

Bipolar Disorder (Manic Depression) (Central Nervous System) - Drugs in Development, 2021 Summary Bipolar Disorder (Manic Depression) (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. The report provides...

  • Bipolar Disorder
  • Neurology
  • World

About Bipolar Disorder Bipolar disorder is also known as manic depression that causes extreme shifts in mood, energy, and activity levels. Elevated mood swings are called mania or hypomania, which differs based on the severity and presence of psychosis. Bipolar disorder is a long-lasting condition that can be categorized...

  • Bipolar Disorder
  • World

‘Excessive Daytime Sleepiness (EDS)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the EDS, historical and forecasted epidemiology as well as the EDS trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. Excessive Daytime Sleepiness (EDS) Disease Understanding Excessive...

  • Epidemiology
  • Bipolar Disorder
  • United States
  • France
  • Japan
  • Germany
  • Italy
  • Spain
  • United Kingdom

This study covers the world outlook for bipolar disorder drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...

  • Bipolar Disorder
  • World
  • Gross Domestic Product
  • Disposable Income

Bipolar Disorder Market Analysis By Drug Class (Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety), By Mechanism of Action, By Region, And Segment Forecasts, 2014 - 2025 The global bipolar disorder market is anticipated to reach USD 4.9 billion by 2025, growing at a CAGR of 2.10% Government...

  • Bipolar Disorder
  • World
  • North America

Bipolar Disorder (Manic Depression) ongoing clinical trials report provides comprehensive analysis and trends in global Bipolar Disorder (Manic Depression) disease clinical trials. The research work analyzes the ongoing Bipolar Disorder (Manic Depression) clinical trial trends across countries and companies. The report focuses on drugs...

  • Bipolar Disorder
  • Clinical Trial
  • World

Drug Overview: Geodon

8770 10000 7800

Drug Overview  Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer. Geodon initially launched in the US in 2001 for the treatment of schizophrenia. It subsequently gained approval for bipolar disorder indications in the US and EU in August 2004 and October...

  • Bipolar Disorder
  • Psychotic Disorder
  • Antipsychotic
  • Japan
  • United States
  • European Union

Drug Overview  Risperdal Consta (Johnson&Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation...

  • Bipolar Disorder
  • Antipsychotic
  • Cardiovascular Drug
  • Hormone
  • United States
  • European Union

Drug Overview  Lamictal (GlaxoSmithKline) contains lamotrigine, a phenyltriazine antiepileptic drug that acts at voltage-sensitive sodium channels to stabilize neuronal membranes and inhibits the release of excitatory amino acid neurotransmitters. Lamictal initially launched as an adjunctive treatment for epilepsy...

  • Bipolar Disorder
  • Antipsychotic
  • Hospital
  • United States
  • European Union

Seroquel/Seroquel XR

8770 10000 7800

Drug Overview  The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors.  AstraZeneca initially launched Seroquel in the...

  • Bipolar Disorder
  • Europe
  • Japan
  • United States

Drug Overview: Zyprexa

8770 10000 7800

Drug Overview Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval...

  • Antipsychotic
  • Bipolar Disorder

Drug Overview  Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor. Abilify’s partial agonist activity at the D2 receptors allows it to act as a dopamine stabilizer...

  • Antipsychotic
  • Cardiovascular Drug
  • Bipolar Disorder
  • United States
  • European Union

Bipolar Disorder (Manic Depression)

  • Bipolar Disorder
  • Depression
  • World
  • Depression Prevalence
  • Diagnostic Imaging Density

Fore Pharma announced the results of its Bipolar Disorder patients study in a new report ‘Global Bipolar Disorder Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Bipolar Disorder epidemiology, Bipolar Disorder diagnosed patients, and Bipolar Disorder treatment rate for top seven pharmaceutical...

  • Bipolar Disorder
  • World
  • Spain
  • France
  • Japan
  • Germany
  • United States
  • Italy
  • United Kingdom

The 5 Key Questions Addressed by this Report: • How many physicians were reached by Seroquel XR through personal promotion in 2016 and how does this compare to its peer set in the Bipolar Disorder, Manic Episodes, and Schizophrenia markets? • What promotional mix was leveraged (e.g., sales rep detailing, physician education,...

  • Health Care Provider
  • Bipolar Disorder
  • United States

Fore Pharma announced the results of its Bipolar Disorder patients study in a new report ‘Europe Bipolar Disorder Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Bipolar Disorder epidemiology, Bipolar Disorder diagnosed patients, and Bipolar Disorder treatment rate for EU5 pharmaceutical markets....

  • Bipolar Disorder
  • Europe

The latest report from Fore Pharma, Bipolar Disorder Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Bipolar Disorder market. It covers emerging therapies for Bipolar Disorder in active clinical development stages including early and late stage clinical trials. The pipeline...

  • Clinical Trial
  • Bipolar Disorder
  • United States
  • World

## TREATMENT: BIPOLAR DISORDER

  • Bipolar Disorder
  • United States
  • Japan
  • European Union
  • Depression Prevalence
  • Drug Approval

Bipolar Disorder (Manic Depression) - Dormant Projects, H## 2016

  • Bipolar Disorder
  • World
  • Diagnostic Imaging Density
  • Depression Prevalence

The latest research from Fore Pharma, Europe Bipolar Disorder Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Bipolar Disorder pipeline products, Bipolar Disorder epidemiology, Bipolar Disorder market valuations and forecast, Bipolar Disorder products sales and competitive landscape. The research...

  • Bipolar Disorder
  • Europe
  • Germany
  • Spain
  • France
  • Italy

The latest research from Fore Pharma, Global Bipolar Disorder Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Bipolar Disorder pipeline products, Bipolar Disorder epidemiology, Bipolar Disorder market valuations and forecast, Bipolar Disorder products and competitive landscape. The research...

  • Bipolar Disorder
  • Spain
  • France
  • Germany
  • United States
  • Italy
  • United Kingdom
  • World
  • Japan

##.## Diagnosed Bipolar Disorder Patients

  • Bipolar Disorder
  • World
  • Drug Approval
  • Prescription Drug Sales

Table ##: Risk Factors and Comorbidities for Bipolar Disorder

  • Bipolar Disorder
  • United States
  • Japan
  • Canada
  • World
  • Depression Prevalence
  • Smoking Prevalence

Table ##: Treatment Guidelines for Bipolar Disorder

  • Bipolar Disorder
  • World
  • Depression Prevalence
  • Drug Approval

Table ##: Treatment Guidelines for Bipolar Disorder

  • Bipolar Disorder
  • World
  • Depression Prevalence
  • Drug Approval

Table ##: Treatment Guidelines for Bipolar Disorder

  • Bipolar Disorder
  • World
  • Depression Prevalence
  • Drug Approval